Delavirdine

Summary

Delavirdine (CHEMBL593) is an approved small-molecule HIV-1 reverse transcriptase inhibitor (ATC J05AG02); indicated across 2 conditions including viral infectious disease and hiv infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J05AG02
• Indications: 2 conditions
• Clinical trials: 1
• Chemistry: 456.6 Da · C22H28N6O3S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL593
Name	Delavirdine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5625
ChEBI	CHEBI:119573
ATC	J05AG02
Molecular formula	C22H28N6O3S
Molecular weight	456.6
InChIKey	WHBIGIKBNXZKFE-UHFFFAOYSA-N

SMILES: CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C

IUPAC name: N-[2-[4-[3-(propan-2-ylamino)-2-pyridinyl]piperazine-1-carbonyl]-1H-indol-5-yl]methanesulfonamide

ChEBI definition: The amide resulting from the formal condensation of 5-[(methylsulfonyl)amino]-1H-indole-2-carboxylic acid and 4-amino group of 1-[3-(isopropylamino)pyridin-2-yl]piperazine, delavirdine is a non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. Viral resistance emerges rapidly when delavirdine is used alone, so it is therefore used (as the methanesulfonic acid salt) with other antiretrovirals for combination therapy of HIV infection.

Pharmacological roles (ChEBI): HIV-1 reverse transcriptase inhibitor, antiviral drug.

Also known as: Delavirdina, Delavirdine, U-90152, delaviridine, delavirdine, Delaverdine, SID50113278, Delaviridine, SID144206190, DELAVIRDINE, SID170464664

Parent form; salt/anhydrous children: CHEMBL929

Patent coverage: 6,407 distinct patent families (25,453 SureChEMBL compound mentions), from 4 matched compound structure(s). One matched structure accounts for 25,443 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 11 (assay-derived). Sample: Nuclear receptor ROR-gamma, Alpha-2A adrenergic receptor, Amine oxidase [flavin-containing] A, Beta-lactamase, Thromboxane A2 receptor, Muscarinic acetylcholine receptor M1, Mu-type opioid receptor, Voltage-gated inwardly rectifying potassium channel KCNH2, Adenosine receptor A3, Malate dehydrogenase, cytoplasmic.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
viral infectious disease	4	MONDO:0005108	EFO:0000763
HIV infectious disease	2	MONDO:0005109	EFO:0000764

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02249130	PHASE2	COMPLETED	Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).